Fund Overlap
See which holdings any two equity ETFs have in common, along with top differences in exposure.
For overlap across multiple ETFs use Portfolio Builder
25
Number of overlapping holdings
21.2%
% of XBI's 119 holdings also in CANC
51.0%
% of CANC's 49 holdings also in XBI
Overlap by Weight
Sector Drift (XBI minus CANC)
Overlapping Holdings
Top 5 only shown here. Please log-in or sign up for a Basic (Free) membership to view the complete list.
| Company | Weight in XBI |
Weight in CANC |
Overlap | |
|---|---|---|---|---|
 |
BLUEPRINT MEDICINES CORP. | 2.5% | 2.8% | 2.5% |
|
AMGEN INC | 2.3% | 2.7% | 2.3% |
|
EXELIXIS INC | 2.1% | 3.9% | 2.1% |
|
ABBVIE INC | 2.4% | 2.0% | 2.0% |
|
BRIDGEBIO PHARMA, INC. | 1.8% | 4.3% | 1.8% |
Position Highlights (Non-Overlapping Exposures)
XBI Overweight Relative to CANC
|
EXACT SCIENCES CORP | 3.1% |
|
NEUROCRINE BIOSCIENCES INC | 2.9% |
|
NATERA INC | 2.9% |
|
ALNYLAM PHARMACEUTICALS INC | 2.8% |
|
UNITED THERAPEUTICS CORP | 2.7% |
|
INSMED INC | 2.4% |
|
VERTEX PHARMACEUTICALS INC | 2.4% |
|
BIOGEN IDEC INC | 2.3% |
|
MADRIGAL PHARMACEUTICALS, INC. | 2.2% |
|
BIOMARIN PHARMACEUTICAL INC | 2.0% |
XBI Underweight Relative to CANC
 |
ROCHE HOLDINGS LTD-SPONS ADR | -5.1% |
|
ELI LILLY & CO | -4.8% |
|
REVOLUTION MEDICINES, INC. | -4.6% |
|
NOVARTIS AG | -4.3% |
 |
ASTRAZENECA PLC | -4.3% |
|
BRISTOL-MYERS SQUIBB CO | -3.8% |
 |
GENMAB A/S SPONSORED ADR | -3.5% |
 |
ZAI LAB LTD. UNSPONSORED ADR | -3.1% |
 |
MERUS N.V. | -3.1% |
|
NUVALENT, INC. CLASS A | -3.0% |